Literature DB >> 7760365

Cardioprotection in an in vitro model of hypoxic preconditioning.

K A Webster1, D J Discher, N H Bishopric.   

Abstract

Short periods of myocardial ischemia appear to provide protection against subsequent prolonged ischemic episodes in experimental animals and in man. This phenomenon, known as ischemic preconditioning, has not yet been characterized at the cellular or molecular levels; however, tissue hypoxia appears to be required. In this study, we used a previously developed method for hypoxic cardiac myocyte culture in order to establish a model for ischemic (or hypoxic) preconditioning in cell culture. We demonstrate that cultured neonatal rat cardiac myocytes preconditioned by 25 min of exposure to hypoxia followed by reoxygenation were protected against membrane damage for up to 6 h of prolonged severe hypoxia, as determined by arachidonic acid release and contractile recovery. In contrast, non-preconditioned myocytes exhibited significant hypoxic damage after 2-4 h. Pretreatment of cells with PMA, a tumor-promoting phorbol ester, mimicked the protective effects of hypoxic preconditioning; pretreatment with the muscarinic cholinergic agonist carbachol had no effect. Our data suggests that isolated myocytes in culture remain competent to be preconditioned by hypoxia, through a pathway that may involve the activation of protein kinase C.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7760365     DOI: 10.1016/s0022-2828(08)80041-7

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  10 in total

1.  Calcium preconditioning triggers neuroprotection in retinal ganglion cells.

Authors:  S K Brandt; M E Weatherly; L Ware; D M Linn; C L Linn
Journal:  Neuroscience       Date:  2010-10-31       Impact factor: 3.590

2.  The virtue of just enough stress: a molecular model.

Authors:  Nanette H Bishopric
Journal:  Trans Am Clin Climatol Assoc       Date:  2012

3.  Direct preconditioning of cultured chick ventricular myocytes. Novel functions of cardiac adenosine A2a and A3 receptors.

Authors:  J Strickler; K A Jacobson; B T Liang
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

4.  Inhibition of endoplasmic reticulum stress by intermedin(1-53) protects against myocardial injury through a PI3 kinase-Akt signaling pathway.

Authors:  Xu Teng; Junqiu Song; Gaigai Zhang; Yan Cai; Fang Yuan; Jie Du; Chaoshu Tang; Yongfen Qi
Journal:  J Mol Med (Berl)       Date:  2011-09-11       Impact factor: 4.599

Review 5.  Adenosine and ischemic preconditioning.

Authors:  B T Liang; K A Jacobson
Journal:  Curr Pharm Des       Date:  1999-12       Impact factor: 3.116

6.  Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for hypoxic preconditioning-mediated delayed cardioprotection.

Authors:  Xiao-Shan Huang; He-Ping Chen; Hai-Hong Yu; Yu-Feng Yan; Zhang-Ping Liao; Qi-Ren Huang
Journal:  Mol Cell Biochem       Date:  2013-09-19       Impact factor: 3.396

7.  CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure.

Authors:  Michael Fiegl; Ismael Samudio; Karen Clise-Dwyer; Jared K Burks; Zakar Mnjoyan; Michael Andreeff
Journal:  Blood       Date:  2008-10-28       Impact factor: 22.113

Review 8.  What can we learn about stroke from retinal ischemia models?

Authors:  Philippe M D'Onofrio; Paulo D Koeberle
Journal:  Acta Pharmacol Sin       Date:  2012-12-03       Impact factor: 6.150

9.  Nucleolin promotes Ang II‑induced phenotypic transformation of vascular smooth muscle cells via interaction with tropoelastin mRNA.

Authors:  Li Fang; Peng-Fei Zhang; Kang-Kai Wang; Zhi-Lin Xiao; Mei Yang; Zai-Xin Yu
Journal:  Int J Mol Med       Date:  2019-02-04       Impact factor: 4.101

10.  Acute Hypobaric and Hypoxic Preconditioning Reduces Myocardial Ischemia-Reperfusion Injury in Rats.

Authors:  Hirofumi Terada; Naoyuki Hirata; Yasuaki Sawashita; Sho Ohno; Yusuke Yoshikawa; Michiaki Yamakage
Journal:  Cardiol Res Pract       Date:  2021-03-16       Impact factor: 1.866

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.